Meng-Rui Lee1, Chia-Hao Chang2, Lih-Yu Chang2, Yu-Chung Chuang3, Hsin-Yun Sun3, Jann-Tay Wang3, Jann-Yuan Wang4. 1. Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. 2. Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: jywang@ntu.edu.tw.
Abstract
BACKGROUND: Clinical application of the CD8 response as measured by the newer interferon gamma release assay, QuantiFERON-TB Gold-Plus (QFT-Plus), remains to be investigated. METHOD: We performed this prospective study and recruited active TB patients, contacts with latent tuberculosis infection (LTBI) and contacts without LTBI in two centres in northern Taiwan in 2017. Subjects were tested with both QuantiFERON-TB Gold In-Tube (QFT-GIT) and QFT-Plus. LTBI was defined by positive result by QFT-GIT and exclusion of active TB. RESULTS: A total of 336 participants (118 uninfected contacts, 105 LTBI, 113 active TB) were included. The concordance rate of QFT-GIT and QFT-Plus was high (n = 300, 89.3%). The kappa value was 0.811 among contacts and 0.708 among active TB. While TB1 and TB2 quantitative responses were not different between active TB and LTBI (TB1: 1.74 ± 2.73 IU/ml vs. 2.03 ± 2.28 IU/ml, p = 0.403; TB2: 2.21 ± 3.09 IU/ml vs. 2.15 ± 2.40 IU/ml, p = 0.867), CD8 response was higher in active TB than LTBI (0.47 ± 1.53 IU/ml vs. -0.06 ± 1.47 IU/ml, p = 0.011). Culture-confirmed TB had a higher CD8 response compared with LTBI (0.63 ± 1.74 IU/ml vs. -0.05 ± 1.47 IU/ml, p = 0.004). CONCLUSIONS: This study demonstrated specific CD8 responses among uninfected contacts, LTBI as well as active TB.
BACKGROUND: Clinical application of the CD8 response as measured by the newer interferon gamma release assay, QuantiFERON-TB Gold-Plus (QFT-Plus), remains to be investigated. METHOD: We performed this prospective study and recruited active TBpatients, contacts with latent tuberculosis infection (LTBI) and contacts without LTBI in two centres in northern Taiwan in 2017. Subjects were tested with both QuantiFERON-TB Gold In-Tube (QFT-GIT) and QFT-Plus. LTBI was defined by positive result by QFT-GIT and exclusion of active TB. RESULTS: A total of 336 participants (118 uninfected contacts, 105 LTBI, 113 active TB) were included. The concordance rate of QFT-GIT and QFT-Plus was high (n = 300, 89.3%). The kappa value was 0.811 among contacts and 0.708 among active TB. While TB1 and TB2 quantitative responses were not different between active TB and LTBI (TB1: 1.74 ± 2.73 IU/ml vs. 2.03 ± 2.28 IU/ml, p = 0.403; TB2: 2.21 ± 3.09 IU/ml vs. 2.15 ± 2.40 IU/ml, p = 0.867), CD8 response was higher in active TB than LTBI (0.47 ± 1.53 IU/ml vs. -0.06 ± 1.47 IU/ml, p = 0.011). Culture-confirmed TB had a higher CD8 response compared with LTBI (0.63 ± 1.74 IU/ml vs. -0.05 ± 1.47 IU/ml, p = 0.004). CONCLUSIONS: This study demonstrated specific CD8 responses among uninfected contacts, LTBI as well as active TB.
Authors: A Wikell; J Jonsson; R Dyrdak; A J Henningsson; A Eringfält; T Kjerstadius; E Hålldin; H Baqir; V Kholod; E Sturegård; J Bruchfeld; T Schön Journal: J Clin Microbiol Date: 2021-09-22 Impact factor: 5.948
Authors: Lena Ronge; Rosa Sloot; Karen Du Preez; Alexander W Kay; H Lester Kirchner; Harleen M S Grewal; Anna M Mandalakas; Anneke C Hesseling Journal: Pediatr Infect Dis J Date: 2021-08-01 Impact factor: 3.806